Doua Elamin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Doua Elamin has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Alok A. Khorana
Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA
1 shared publicationAndrew Strong
Cleveland Clinic, Cleveland, USA
1 shared publication- Andrew T. Strong
Digestive Disease Institute, Cleveland Clinic, Ohio; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
1 shared publication - Emre Gorgun
Department of Colorectal Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, USA
1 shared publication - Gustavo Romero-Velez
Section of Endocrine Surgery, Integrated Surgical Institute, Cleveland Clinic, Cleveland, OH; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH
1 shared publication Ilker Ozgur
Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA
1 shared publication
Latest Publications
- 17 August 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 261, 117198
The path to surgical residency as an international medical graduate
- 17 August 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 261, 117198
The path to surgical residency as an international medical graduate
- Open Access
- 27 June 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (8) , 4035-4041
30-Day Outcomes of Simultaneous Sleeve Gastrectomy and Kidney Transplantation: An Analysis from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Database
Background: Obesity limits access to kidney transplantation (KT) and worsens outcomes in patients with end-stage renal disease (ESRD). Sleeve gastrectomy (SG) is increasingly used to facilitate transplant eligibility; however, the safety of simultaneous SG and KT (SG + KT) remains poorly defined at a multi-institutional level. This study evaluates 30-day perioperative outcomes of SG + KT using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database. Methods: A retrospective analysis of the MBSAQIP database (2020–2023) was performed. Adult patients undergoing SG were identified with simultaneous KT and captured using CPT codes. Demographics, comorbidities, operative characteristics, and 30-day outcomes were compared between SG-only and SG + KT cohorts. Multivariable logistic regression was used to identify independent predictors of serious complications and 30-day mortality. Results: Among 582,860 patients undergoing SG, 22 (0.004%) underwent simultaneous KT. SG + KT patients were older, predominantly male, and had significantly higher rates of diabetes, hypertension, renal insufficiency, and dialysis dependence (all p < 0.001), with similar body mass index compared to SG alone. SG + KT was associated with longer operative time, increased length of stay, and higher rates of bleeding, readmission within 30-days and serious complications (all p ≤ 0.001). Thirty-day mortality was significantly higher following SG + KT (9.1% vs. 0.1%, p < 0.001). On multivariable analysis, simultaneous KT was the strongest independent predictor of serious complications (OR 7.97; 95% CI 2.27–27.93; p = 0.001) and mortality (OR 33.99; 95% CI 3.99–289.03; p = 0.001). Conclusion: Simultaneous sleeve gastrectomy and kidney transplantation is exceedingly rare and associated with markedly increased 30-day morbidity and mortality compared with sleeve gastrectomy alone, highlighting the need for careful patient selection and multidisciplinary risk assessment.
- 27 June 2026
- Published by Springer Nature in Obesity Surgery
- Vol. 36 (8) , 4035-4041
Open Access30-Day Outcomes of Simultaneous Sleeve Gastrectomy and Kidney Transplantation: An Analysis from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) Database
Background: Obesity limits access to kidney transplantation (KT) and worsens outcomes in patients with end-stage renal disease (ESRD). Sleeve gastrectomy (SG) is increasingly used to facilitate transplant eligibility; however, the safety of simultaneous SG and KT (SG + KT) remains poorly defined at a multi-institutional level. This study evaluates 30-day perioperative outcomes of SG + KT using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database. Methods: A retrospective analysis of the MBSAQIP database (2020–2023) was performed. Adult patients undergoing SG were identified with simultaneous KT and captured using CPT codes. Demographics, comorbidities, operative characteristics, and 30-day outcomes were compared between SG-only and SG + KT cohorts. Multivariable logistic regression was used to identify independent predictors of serious complications and 30-day mortality. Results: Among 582,860 patients undergoing SG, 22 (0.004%) underwent simultaneous KT. SG + KT patients were older, predominantly male, and had significantly higher rates of diabetes, hypertension, renal insufficiency, and dialysis dependence (all p < 0.001), with similar body mass index compared to SG alone. SG + KT was associated with longer operative time, increased length of stay, and higher rates of bleeding, readmission within 30-days and serious complications (all p ≤ 0.001). Thirty-day mortality was significantly higher following SG + KT (9.1% vs. 0.1%, p < 0.001). On multivariable analysis, simultaneous KT was the strongest independent predictor of serious complications (OR 7.97; 95% CI 2.27–27.93; p = 0.001) and mortality (OR 33.99; 95% CI 3.99–289.03; p = 0.001). Conclusion: Simultaneous sleeve gastrectomy and kidney transplantation is exceedingly rare and associated with markedly increased 30-day morbidity and mortality compared with sleeve gastrectomy alone, highlighting the need for careful patient selection and multidisciplinary risk assessment.
- Open Access
- 25 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5262
Counting Limb Length Ratios in Roux-en-Y Gastric Bypass: A Demonstration of Safety and Feasibility Using a 25-Patient Case Series in a High-Volume Academic Center
Background: Despite being one of the most performed bariatric procedures, there is no consensus regarding optimal limb lengths for Roux-en-Y gastric bypass (RYGB), which may impact weight loss and obesity-related comorbidity resolution. We hypothesize that a ratio-adjusted small bowel to Roux and BP limb lengths in RYGB results in superior outcomes. Objectives: This study aims to define total intestinal length (TIL) and the feasibility of its intraoperative measurement during RYGB. The findings will serve as a foundation for a subsequent randomized trial evaluating different limb length ratios and their effect on postoperative outcomes. Setting: This was a single-center prospective cohort study conducted at Cleveland Clinic Foundation-Main Campus, a tertiary referral center in the United States. Methods: Between January and June 2023, 25 patients with BMI > 40 undergoing RYGB were enrolled. Total small bowel length was measured intraoperatively, and feasibility of measurement was assessed. Patient outcomes, including total weight loss, 30-day complications, and comorbidities at 1 year were captured. Results: Mean preoperative BMI was 47.6 ± 8.0 kg/m2. Mean total small bowel length was 592 ± 93.3 cm, with a mean biliopancreatic (BP) limb length of 109 ± 29 cm (18.86% ± 5.84 of total length) and Roux limb length of 103 ± 15 cm (17.71% ± 3.06 of total length). Measurement added an average of 11.5 min to operative time. Measurement feasibility was rated as “moderate” or easier in 80% of cases. One-year postoperative outcomes included a mean total weight loss of 31% and significant reductions in antihypertensive and anti-diabetic medication use. Conclusions: Total small bowel length measurement during RYGB is safe and feasible. High variability in bowel length was observed, with no significant correlation to demographic factors. Establishing individualized limb length ratios may improve weight loss outcomes and comorbidity resolution. Further studies are warranted to evaluate the impact of tailored limb length strategies.
- 25 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5262
Open AccessCounting Limb Length Ratios in Roux-en-Y Gastric Bypass: A Demonstration of Safety and Feasibility Using a 25-Patient Case Series in a High-Volume Academic Center
Background: Despite being one of the most performed bariatric procedures, there is no consensus regarding optimal limb lengths for Roux-en-Y gastric bypass (RYGB), which may impact weight loss and obesity-related comorbidity resolution. We hypothesize that a ratio-adjusted small bowel to Roux and BP limb lengths in RYGB results in superior outcomes. Objectives: This study aims to define total intestinal length (TIL) and the feasibility of its intraoperative measurement during RYGB. The findings will serve as a foundation for a subsequent randomized trial evaluating different limb length ratios and their effect on postoperative outcomes. Setting: This was a single-center prospective cohort study conducted at Cleveland Clinic Foundation-Main Campus, a tertiary referral center in the United States. Methods: Between January and June 2023, 25 patients with BMI > 40 undergoing RYGB were enrolled. Total small bowel length was measured intraoperatively, and feasibility of measurement was assessed. Patient outcomes, including total weight loss, 30-day complications, and comorbidities at 1 year were captured. Results: Mean preoperative BMI was 47.6 ± 8.0 kg/m2. Mean total small bowel length was 592 ± 93.3 cm, with a mean biliopancreatic (BP) limb length of 109 ± 29 cm (18.86% ± 5.84 of total length) and Roux limb length of 103 ± 15 cm (17.71% ± 3.06 of total length). Measurement added an average of 11.5 min to operative time. Measurement feasibility was rated as “moderate” or easier in 80% of cases. One-year postoperative outcomes included a mean total weight loss of 31% and significant reductions in antihypertensive and anti-diabetic medication use. Conclusions: Total small bowel length measurement during RYGB is safe and feasible. High variability in bowel length was observed, with no significant correlation to demographic factors. Establishing individualized limb length ratios may improve weight loss outcomes and comorbidity resolution. Further studies are warranted to evaluate the impact of tailored limb length strategies.
- 31 January 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 225 (5) , 934-936
Impact of COVID-19 pandemic on treatment of colorectal cancer patients
- 31 January 2023
- Published by Elsevier in The American Journal of Surgery
- Vol. 225 (5) , 934-936
Impact of COVID-19 pandemic on treatment of colorectal cancer patients